# US 6,727,223 B2 · Treatment of microbial infections with bacterial proteins and peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,223 B2
- Document ID: US6727223B2
- Status: Granted
- Kind: B2
- Application number: 09/921,880
- Filed: 2001-08-03
- Published: 2002-08-29
- Granted: 2004-04-27
- Earliest claimed: 2000-08-04
- Assignees: Urex Biotech, Inc.
- Inventors: Jeffrey Howard; Gregor Reid; Bing Siang Gan
- Web page: https://patentgrep.com/patent/US6727223B2

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 31/04: Antibacterial agents
- C07K 14/31: from Staphylococcus (G)
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C07K 14/335: from Lactobacillus (G)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to protein and peptide chemistry. In particular, the present invention relates to the discovery and isolation of novel peptides whose sequences derive from microorganism by-products including biosurfactants. The invention is also directed to the use of these novel peptides in the inhibition of infections caused by pathogens.

## Claims

### Claim 1

An isolated biosurfactant peptide comprising Glu-Val-Tyr-Xaa1-Phe-Gln-Glu-Xaa2-Xaa3-Arg (SEQ ID NO: 2), wherein Xaa1 is any amino acid and Xaa2 and Xaa3 are selected from the group consisting of Gln or Pro.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the peptide of claim 1, and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

A method of treating an infection in a subject, comprising administering to the subject a therapeutically effective amount of the peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1)

A method of inhibiting the binding of a pathogen to a collagen receptor comprising the administration to a subject a therapeutically effective amount of the peptide of claim 1.

### Claim 5 (depends on 1)

A method of inhibiting an infection in a subject comprising blocking the interaction of a pathogen with a collagen receptor by the administration of a therapeutically effective amount of the biosurfactant claim 1.
